The Global HIV Vaccine Enterprise and the New York Academy of Sciences will present HIV/AIDS: Vaccines and Alternate Strategies for Treatment and Prevention, a daylong meeting at the New York Academy of Sciences on May 19, 2010.

The OCTAVE Project (Online Collaborative Training for AIDS Vaccine Evaluation) and the Global HIV Vaccine Enterprise, in collaboration with AVAC: Global Advocacy for HIV Prevention and UNAIDS, are organizing an interactive workshop for Young and Early Career Investigators (YECIs). This workshop will focus on the process to engage community stakeholders in planning and conducting HIV biomedical prevention research.

IAVI and biotechnology company, Lentigen Corporation, announced a collaboration to design a preventive AIDS vaccine based on Lentigen's technology.

Steady advances are being made in the search for an HIV/AIDS vaccine, according to a new overview of research presented at the AIDS Vaccine 2009 Conference published in the May 2010 edition of The Lancet Infectious Diseases.

The Enterprise Council met on 7 April 2010.  Minutes from the meeting are below.

The Enterprise Board met on 6 April 2010.  Minutes from the meeting are below.

The African AIDS Vaccine Initiative (AAVP) is recruiting for an Executive Director.  The description is attached below. 

The KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) is hosting a

The Global HIV Vaccine Enterprise, the organizer of the annual AIDS Vaccine conference, is accepting applications for Local Host of AIDS Vaccine 2012 to be held in North America. The annual AIDS Vaccine conference is the largest and most important global scientific conference focused on AIDS vaccine research. Interested applicants should review and complete the attached application form and submit to Amapola Manrique (amanrique@vaccineenterprise.org) by March 15, 2010.

The Uganda Virus Research Institute (UVRI) based in Entebbe, Uganda was recommended to host the Secretariat of the African AIDS Vaccine Programme (AAVP), an initiative to support a coordinated international effort to promote the development of and future access to HIV vaccines suitable for use in Africa. The AAVP Secretariat has been based in Geneva, Switzerland since 2000. A transition of AAVP to a fully functional African programme began more than a year ago and should be complete by the first quarter of 2010.